Peptides最新文献_第8页

Nisin variants: What makes them different and unique? Nisin 变体：它们有何不同和独特之处？

IF 3 4区医学

Peptides Pub Date : 2024-04-16 DOI: 10.1016/j.peptides.2024.171220

Weslei da Silva Oliveira , César Roberto Viana Teixeira , Hilário Cuquetto Mantovani , Silvio Santana Dolabella , Sona Jain , Ana Andréa Teixeira Barbosa

{"title":"Nisin variants: What makes them different and unique?","authors":"Weslei da Silva Oliveira , César Roberto Viana Teixeira , Hilário Cuquetto Mantovani , Silvio Santana Dolabella , Sona Jain , Ana Andréa Teixeira Barbosa","doi":"10.1016/j.peptides.2024.171220","DOIUrl":"10.1016/j.peptides.2024.171220","url":null,"abstract":"<div><p>Nisin A is a lantibiotic bacteriocin typically produced by strains of <em>Lactococcus lactis</em>. This bacteriocin has been approved as a natural food preservative since the late 1980 s and shows antimicrobial activity against a range of food-borne spoilage and pathogenic microorganisms. The therapeutic potential of nisin A has also been explored increasingly both in human and veterinary medicine. Nisin has been shown to be effective in treating bovine mastitis, dental caries, cancer, and skin infections. Recently, it was demonstrated that nisin has an affinity for the same receptor used by SARS-CoV-2 to enter human cells and was proposed as a blocker of the viral infection. Several nisin variants produced by distinct bacterial strains or modified by bioengineering have been described since the discovery of nisin A. These variants present modifications in the peptide structure, biosynthesis, mode of action, and spectrum of activity. Given the importance of nisin for industrial and therapeutic applications, the objective of this study was to describe the characteristics of the nisin variants, highlighting the main differences between these molecules and their potential applications. This review will be useful to researchers interested in studying the specifics of nisin A and its variants.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"177 ","pages":"Article 171220"},"PeriodicalIF":3.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140756519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Attachment-like behavioral expressions to humans in puppies are related to oxytocin and cortisol: A comparative study of Akitas and Labrador Retrievers 幼犬对人类的类依恋行为表现与催产素和皮质醇有关：对秋田犬和拉布拉多寻回犬的比较研究。

IF 3 4区医学

Peptides Pub Date : 2024-04-16 DOI: 10.1016/j.peptides.2024.171224

Miho Nagasawa, Sakiko Tomori, Kazutaka Mogi, Takefumi Kikusui

{"title":"Attachment-like behavioral expressions to humans in puppies are related to oxytocin and cortisol: A comparative study of Akitas and Labrador Retrievers","authors":"Miho Nagasawa, Sakiko Tomori, Kazutaka Mogi, Takefumi Kikusui","doi":"10.1016/j.peptides.2024.171224","DOIUrl":"10.1016/j.peptides.2024.171224","url":null,"abstract":"<div><p>This study investigated the relationship between urinary hormone concentrations and attachment-related behaviors in two dog breeds, the Akitas and Labrador Retrievers, to elucidate the hormonal and behavioral mechanisms underlying domestication and interspecies attachment to humans. By measuring cortisol and oxytocin concentrations, and conducting the Strange Situation Test (SST), we aimed to investigate breed differences in endocrine secretions associated with domestication and how these differences influence dog behavior toward humans. Our results showed significant breed differences in urinary cortisol concentrations, with Akitas exhibiting higher levels than Labrador Retrievers. This suggests a breed-specific stress response related to genetic proximity to wolves. However, oxytocin concentrations did not differ significantly, which suggests a complex interplay between factors influencing the domestication process and the formation of attachment behaviors. Behavioral observations during the SST revealed breed-specific patterns, with Labrador Retrievers showing more playful and attachment-like behaviors and Akitas showing more exploratory and passive behaviors. The study found correlations between hormones and behaviors within breeds, particularly in Labrador Retrievers, where oxytocin concentrations were associated with attachment-like behaviors, and cortisol concentrations reflected individual differences in physical activity rather than stress responses to social situations. These findings contribute to the understanding of the evolutionary and adaptive processes underlying the ability of domestic dogs to form close relationships with humans while highlighting the role of hormonal mechanisms in mediating attachment behaviors and the influence of breed-specific genetic backgrounds on these processes.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"177 ","pages":"Article 171224"},"PeriodicalIF":3.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140771909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuropeptides affecting social behavior in mammals: Oxytocin 影响哺乳动物社交行为的神经肽：催产素

IF 3 4区医学

Peptides Pub Date : 2024-04-14 DOI: 10.1016/j.peptides.2024.171223

Hong Zhou , Rui Zhu , Yuqing Xia , Xinming Zhang , Zixu Wang , George H. Lorimer , Reza A. Ghiladi , Hasan Bayram , Jun Wang

{"title":"Neuropeptides affecting social behavior in mammals: Oxytocin","authors":"Hong Zhou , Rui Zhu , Yuqing Xia , Xinming Zhang , Zixu Wang , George H. Lorimer , Reza A. Ghiladi , Hasan Bayram , Jun Wang","doi":"10.1016/j.peptides.2024.171223","DOIUrl":"https://doi.org/10.1016/j.peptides.2024.171223","url":null,"abstract":"<div><p>Oxytocin (OXT), a neuropeptide consisting of only nine amino acids, is synthesized in the paraventricular and supraoptic nuclei of the hypothalamus. Although OXT is best known for its role in lactation and parturition, recent research has shown that it also has a significant impact on social behaviors in mammals. However, a comprehensive review of this topic is still lacking. In this paper, we systematically reviewed the effects of OXT on social behavior in mammals. These effects of OXT from the perspective of five key behavioral dimensions were summarized: parental behavior, anxiety, aggression, attachment, and empathy. To date, researchers have agreed that OXT plays a positive regulatory role in a wide range of social behaviors, but there have been controversially reported results. In this review, we have provided a detailed panorama of the role of OXT in social behavior and, for the first time, delved into the underlying regulatory mechanisms, which may help better understand the multifaceted role of OXT. Levels of OXT in previous human studies were also summarized to provide insights for diagnosis of mental disorders.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"177 ","pages":"Article 171223"},"PeriodicalIF":3.0,"publicationDate":"2024-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140650191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Functional role of immunoglobulin G as an oxytocin-carrier protein 免疫球蛋白 G 作为催产素载体蛋白的功能作用

IF 3 4区医学

Peptides Pub Date : 2024-04-14 DOI: 10.1016/j.peptides.2024.171221

Emilie Lahaye, Sergueï O. Fetissov

引用次数: 0

Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice FFAR4/GPR120、DPP-IV 抑制剂和 GLP-1 在肥胖高脂喂养小鼠β细胞增殖和葡萄糖稳态中的积极相互作用

IF 3 4区医学

Peptides Pub Date : 2024-04-14 DOI: 10.1016/j.peptides.2024.171218

A.I. Owolabi, R.C. Corbett, P.R. Flatt, A.M. McKillop

{"title":"Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice","authors":"A.I. Owolabi, R.C. Corbett, P.R. Flatt, A.M. McKillop","doi":"10.1016/j.peptides.2024.171218","DOIUrl":"10.1016/j.peptides.2024.171218","url":null,"abstract":"<div><p>G-protein coupled receptor-120 (GPR120; <em>FFAR4</em>) is a free fatty acid receptor, widely researched for its glucoregulatory and insulin release activities. This study aimed to investigate the metabolic advantage of FFAR4/GPR120 activation using combination therapy. C57BL/6 mice, fed a High Fat Diet (HFD) for 120 days to induce obesity-diabetes, were subsequently treated with a single daily oral dose of FFAR4/GPR120 agonist Compound A (CpdA) (0.1μmol/kg) alone or in combination with sitagliptin (50 mg/kg) for 21 days. After 21-days, glucose homeostasis, islet morphology, plasma hormones and lipids, tissue genes (qPCR) and protein expression (immunocytochemistry) were assessed. Oral administration of CpdA improved glucose tolerance (34% p<0.001) and increased circulating insulin (38% p<0.001). Addition of CpdA with the dipeptidyl peptidase-IV (DPP-IV) inhibitor, sitagliptin, further improved insulin release (44%) compared to sitagliptin alone and reduced fat mass (p<0.05). CpdA alone (50%) and in combination with sitagliptin (89%) induced marked reductions in LDL-cholesterol, with greater effects in combination (p<0.05). All treatment regimens restored pancreatic islet and beta-cell area and mass, complemented with significantly elevated beta-cell proliferation rates. A marked increase in circulating GLP-1 (53%) was observed, with further increases in combination (38%). With treatment, mice presented with increased <em>Gcg</em> (proglucagon) gene expression in the jejunum (130% increase) and ileum (120% increase), indicative of GLP-1 synthesis and secretion. These data highlight the therapeutic promise of FFAR4/GPR120 activation and the potential for combined benefit with incretin enhancing DPP-IV inhibitors in the regulation of beta cell proliferation and diabetes.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"177 ","pages":"Article 171218"},"PeriodicalIF":3.0,"publicationDate":"2024-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0196978124000718/pdfft?md5=00b12a466d31f791dabd1fa8b9a1c076&pid=1-s2.0-S0196978124000718-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140708548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot? 针对糖尿病和肥胖症患者的胰高血糖素疗法：甜蜜点在哪里？

IF 3 4区医学

Peptides Pub Date : 2024-04-13 DOI: 10.1016/j.peptides.2024.171219

Emma Rose McGlone , Tricia M.-M. Tan

{"title":"Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?","authors":"Emma Rose McGlone , Tricia M.-M. Tan","doi":"10.1016/j.peptides.2024.171219","DOIUrl":"https://doi.org/10.1016/j.peptides.2024.171219","url":null,"abstract":"<div><p>People with obesity and type 2 diabetes have a high prevalence of metabolic-associated steatotic liver disease, hyperlipidemia and cardiovascular disease. Glucagon increases hepatic glucose production; it also decreases hepatic fat accumulation, improves lipidemia and increases energy expenditure. Pharmaceutical strategies to antagonize the glucagon receptor improve glycemic outcomes in people with diabetes and obesity, but they increase hepatic steatosis and worsen dyslipidemia. Co-agonism of the glucagon and glucagon-like peptide-1 (GLP-1) receptors has emerged as a promising strategy to improve glycemia in people with diabetes and obesity. Addition of glucagon receptor agonism enhances weight loss, reduces liver fat and ameliorates dyslipidemia. Prior to clinical use, however, further studies are needed to investigate the safety and efficacy of glucagon and GLP-1 receptor co-agonists in people with diabetes and obesity and related conditions, with specific concerns regarding a higher prevalence of gastrointestinal side effects, loss of muscle mass and increases in heart rate. Furthermore, co-agonists with differing ratios of glucagon:GLP-1 receptor activity vary in their clinical effect; the optimum balance is yet to be identified.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"176 ","pages":"Article 171219"},"PeriodicalIF":3.0,"publicationDate":"2024-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S019697812400072X/pdfft?md5=0655069d2d8f2cc91f7cd1e467464703&pid=1-s2.0-S019697812400072X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140558083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Negative association between basal oxytocin and oxytocin changes after repetitive transcranial magnetic stimulation in patients with treatment-resistant depression 耐药性抑郁症患者的基础催产素与重复经颅磁刺激后催产素变化之间存在负相关关系

IF 3 4区医学

Peptides Pub Date : 2024-04-13 DOI: 10.1016/j.peptides.2024.171217

Ryohei Kojima , Hiroshi Tateishi , Hiroko Kunitake , Yoshiomi Imamura , Yutaka Kunitake , Toru Murakawa , Chika Nagahama , Takumi Shiraishi , Ken Takada , Masataka Hirano , Airi Fukai , Akira Tomonari , Akira Monji , Yoshito Mizoguchi

{"title":"Negative association between basal oxytocin and oxytocin changes after repetitive transcranial magnetic stimulation in patients with treatment-resistant depression","authors":"Ryohei Kojima , Hiroshi Tateishi , Hiroko Kunitake , Yoshiomi Imamura , Yutaka Kunitake , Toru Murakawa , Chika Nagahama , Takumi Shiraishi , Ken Takada , Masataka Hirano , Airi Fukai , Akira Tomonari , Akira Monji , Yoshito Mizoguchi","doi":"10.1016/j.peptides.2024.171217","DOIUrl":"https://doi.org/10.1016/j.peptides.2024.171217","url":null,"abstract":"<div><p>Repetitive transcranial magnetic stimulation (rTMS) is a neuromodulator effective for treating depressive symptoms in patients with treatment-resistant depression (TRD). One of the multiple mechanisms for its antidepressant effects proposed is related to the hypothalamus. Oxytocin is a neuropeptide synthesized in the hypothalamus that affects human behavior and psychology, including social and affiliative behaviors, stress regulation, and fear and emotion processing. There have been no reports on the relationship between rTMS and oxytocin for the treatment of TRD. Therefore, we aimed to investigate changes in salivary oxytocin concentrations in patients with TRD before and after 6 weeks of rTMS treatment. A total of 28 patients with TRD who received rTMS at Saga University Hospital between August 2013 and August 2020 were included. Although rTMS treatment significantly improved 24-item Hamilton Depression Rating Scale scores, rTMS treatment did not change mean salivary oxytocin after 6 weeks of treatment in patients with TRD. Multiple regression analysis revealed that the change in salivary oxytocin levels after rTMS treatment was negatively associated with basal oxytocin levels before rTMS treatment, suggesting that rTMS treatment tends to decrease oxytocin levels in patients with depression with high basal oxytocin levels while increasing them in those with low basal levels. These findings suggest that rTMS treatment improved depressive symptoms through mechanisms other than the modulatory effect on oxytocin levels in patients with TRD, while there is room for further studies to confirm these findings using a larger patient sample size and/or a sham rTMS procedure.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"177 ","pages":"Article 171217"},"PeriodicalIF":3.0,"publicationDate":"2024-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140548953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety of native glucose-dependent insulinotropic polypeptide in humans 原生葡萄糖依赖性促胰岛素多肽对人体的安全性

IF 3 4区医学

Peptides Pub Date : 2024-04-12 DOI: 10.1016/j.peptides.2024.171214

Mads M. Helsted , Nina L. Schaltz , Lærke S. Gasbjerg , Mikkel B. Christensen , Tina Vilsbøll , Filip K. Knop

{"title":"Safety of native glucose-dependent insulinotropic polypeptide in humans","authors":"Mads M. Helsted , Nina L. Schaltz , Lærke S. Gasbjerg , Mikkel B. Christensen , Tina Vilsbøll , Filip K. Knop","doi":"10.1016/j.peptides.2024.171214","DOIUrl":"https://doi.org/10.1016/j.peptides.2024.171214","url":null,"abstract":"<div><p>In this systematic review, we assessed the safety and possible safety events of native glucose-dependent insulinotropic polypeptide (GIP)(1−42) in human studies with administration of synthetic human GIP. We searched the PubMed database for all trials investigating synthetic human GIP(1−42) administration. A total of 67 studies were included. Study duration ranged from 30 min to 6 days. In addition to healthy individuals, the studies included individuals with impaired glucose tolerance, type 2 diabetes, type 1 diabetes, chronic pancreatitis and secondary diabetes, latent autoimmune diabetes in adults, diabetes caused by a mutation in the hepatocyte nuclear factor 1-alpha gene, end-stage renal disease, chronic renal insufficiency, critical illness, hypoparathyroidism, or cystic fibrosis-related diabetes. Of the included studies, 78% did not mention safety events, 10% of the studies reported that no safety events were observed in relation to GIP administration, and 15% of the studies reported safety events in relation to GIP administration with most frequently reported event being a moderate and transient increased heart rate. Gastrointestinal safety events, and changes in blood pressure were also reported. Plasma concentration of active GIP(1−42) increased linearly with dose independent of participant phenotype. There was no significant correlation between achieved maximal concentration of GIP(1−42) and reported safety events. Clearance rates of GIP(1−42) were similar between participant groups. In conclusion, the available data indicate that GIP(1−42) in short-term (up to 6 days) infusion studies is generally well-tolerated. The long-term safety of continuous GIP(1−42) administration is unknown.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"177 ","pages":"Article 171214"},"PeriodicalIF":3.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140618609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Newly identified peptide Nigrocin-OA27 inhibits UVB induced melanin production via the MITF/TYR pathway 新发现的肽 Nigrocin-OA27 通过 MITF/TYR 途径抑制紫外线诱导的黑色素生成

IF 3 4区医学

Peptides Pub Date : 2024-04-11 DOI: 10.1016/j.peptides.2024.171215

Jiayi Li , Saige Yin , Ziqi Wei , Zhaoxun Xiao , Zijian Kang , Yutong Wu , Yubing Huang , Qiuye Jia , Ying Peng , Zeqiong Ru , Xiaohan Sun , Yuliu Yang , Qian Yang , Junyuan Wang , Chengxing Liu , Meifeng Yang , Ying Wang , Xinwang Yang

{"title":"Newly identified peptide Nigrocin-OA27 inhibits UVB induced melanin production via the MITF/TYR pathway","authors":"Jiayi Li , Saige Yin , Ziqi Wei , Zhaoxun Xiao , Zijian Kang , Yutong Wu , Yubing Huang , Qiuye Jia , Ying Peng , Zeqiong Ru , Xiaohan Sun , Yuliu Yang , Qian Yang , Junyuan Wang , Chengxing Liu , Meifeng Yang , Ying Wang , Xinwang Yang","doi":"10.1016/j.peptides.2024.171215","DOIUrl":"https://doi.org/10.1016/j.peptides.2024.171215","url":null,"abstract":"<div><p>Melasma is a common skin disease induced by an increase in the content of melanin in the skin, which also causes serious physical and mental harm to patients. In this research, a novel peptide (Nigrocin-OA27) from <em>Odorrana andersonii</em> is shown to exert a whitening effect on C57 mice pigmentation model. The peptide also demonstrated non-toxic and antioxidant capacity, and can significantly reduce melanin content in B16 cells. Topical application effectively delivered Nigrocin-OA27 to skin's epidermal and dermal layers and exhibited significant preventive and whitening effects on the UVB-induced ear pigmentation model in C57 mice. The whitening mechanism of Nigrocin-OA27 may be related to reduced levels of the microphthalmia-associated transcription factor and the key enzyme for melanogenesis-tyrosinase (TYR). Nigrocin-OA27 also inhibited the catalytic activity by adhering to the active core of TYR, thereby reducing melanin formation and deposition. In conclusion, Nigrocin-OA27 may be a potentially effective external agent to treat melasma by inhibiting aberrant skin melanin synthesis.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"177 ","pages":"Article 171215"},"PeriodicalIF":3.0,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140558516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucagon does not directly stimulate pituitary secretion of ACTH, GH or copeptin 胰高血糖素不会直接刺激垂体分泌促肾上腺皮质激素、促肾上腺皮质激素或促肾上腺皮质激素

IF 3 4区医学

Peptides Pub Date : 2024-04-10 DOI: 10.1016/j.peptides.2024.171213

Ida Stangerup , Sasha A.S. Kjeldsen , Michael M. Richter , Nicole J. Jensen , Jørgen Rungby , Steen Bendix Haugaard , Birgitte Georg , Jens Hannibal , Kjeld Møllgård , Nicolai J. Wewer Albrechtsen , Camilla Bjørnbak Holst

{"title":"Glucagon does not directly stimulate pituitary secretion of ACTH, GH or copeptin","authors":"Ida Stangerup , Sasha A.S. Kjeldsen , Michael M. Richter , Nicole J. Jensen , Jørgen Rungby , Steen Bendix Haugaard , Birgitte Georg , Jens Hannibal , Kjeld Møllgård , Nicolai J. Wewer Albrechtsen , Camilla Bjørnbak Holst","doi":"10.1016/j.peptides.2024.171213","DOIUrl":"https://doi.org/10.1016/j.peptides.2024.171213","url":null,"abstract":"<div><p>Glucagon is best known for its contribution to glucose regulation through activation of the glucagon receptor (GCGR), primarily located in the liver. However, glucagon’s impact on other organs may also contribute to its potent effects in health and disease. Given that glucagon-based medicine is entering the arena of anti-obesity drugs, elucidating extrahepatic actions of glucagon are of increased importance. It has been reported that glucagon may stimulate secretion of arginine-vasopressin (AVP)/copeptin, growth hormone (GH) and adrenocorticotrophic hormone (ACTH) from the pituitary gland. Nevertheless, the mechanisms and whether GCGR is present in human pituitary are unknown. In this study we found that intravenous administration of 0.2 mg glucagon to 14 healthy subjects was not associated with increases in plasma concentrations of copeptin, GH, ACTH or cortisol over a 120-min period. GCGR immunoreactivity was present in the anterior pituitary but not in cells containing GH or ACTH. Collectively, glucagon may not directly stimulate secretion of GH, ACTH or AVP/copeptin in humans but may instead be involved in yet unidentified pituitary functions.</p></div>","PeriodicalId":19765,"journal":{"name":"Peptides","volume":"176 ","pages":"Article 171213"},"PeriodicalIF":3.0,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0196978124000664/pdfft?md5=0aa7ad2a846d81bd5b6470625fb4aadd&pid=1-s2.0-S0196978124000664-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140551244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0